AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04471298
Drug: Qishenyiqi dripping pills placebo, 12 bags
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 consecutive days
Trial: NCT01786824
Drug: Hydration strategy using saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
Trial: NCT03090724
Drug: BIA 5-453
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
Trial: NCT00425971
Drug: BMEC-1217B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01323244
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
Trial: NCT02288078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule filled with lactose
Trial: NCT02288078
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
Trial: NCT00201461
Drug: Best medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
Trial: NCT01037127
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dosing
Trial: NCT03071731
Drug: Bronchodilators
RxNorm normalized name: ANTIASTHMA/BRONCHODILATORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a nebulized combination of bronchodilators before the administration of a functional test.
Trial: NCT03071731
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a nebulized placebo before the administration of a functional test
Trial: NCT01362244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by IV infusion
Trial: NCT02790788
Drug: Methylprednisolone; hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
Trial: NCT02790788
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo during resuscitation and during the postresuscitation phase.
Trial: NCT01450774
Drug: CHF 1535 50/6µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Trial: NCT02191176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00264160
Drug: AMN107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02464891
Drug: CCX168
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004935
Drug: Herceptin™ (Her)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
Trial: NCT00004935
Drug: Herceptin™ (Her) + chemo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
Trial: NCT03335423
Drug: Oral codeine and oral metformin
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
Trial: NCT03335423
Drug: Oral codeine and intravenous metformin
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
Trial: NCT03439189
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo versus emricasan in Conatus NASH treatment trial
Trial: NCT04500860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drugs
Trial: NCT02522013
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03837093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
Trial: NCT05125549
Drug: Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
Trial: NCT05125549
Drug: Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
Trial: NCT03386032
Drug: Investigational OTC Cream
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
Trial: NCT02111499
Drug: LAS41004-IMP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily topical application
Trial: NCT02111499
Drug: LAS41004 IMP2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily topical application
Trial: NCT02111499
Drug: LAS41004 IMP3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily topical application
Trial: NCT02111499
Drug: LAS41004 IMP4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily topical application
Trial: NCT02111499
Drug: LAS41004 IMP5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, topical
Trial: NCT01821040
Drug: Lodotra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lodotra, starting dose of 15mg administered in the evening
Trial: NCT03032965
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate.
Trial: NCT02209805
Drug: BIRB 796 BS, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02209805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03813147
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally
Trial: NCT03813147
Drug: Therapeutic Hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intrathecally
Trial: NCT01063920
Drug: Naprosyn®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg b.i.d. p.o. for 12 weeks
Trial: NCT02916602
Drug: HCP1401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine, Losartan, Chlorthalidone FDC
Trial: NCT02916602
Drug: HCP0605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine, Losartan FDC
Trial: NCT00485225
Drug: EN3270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Therapeutic System
Trial: NCT03806231
Drug: Outpatient Dinoprostone 10mg
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
Trial: NCT01184105
Drug: Intervention B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
Trial: NCT03806231
Drug: Inpatient Dinoprostone 10 mg
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
Trial: NCT04106050
Drug: BIIB095
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04106050
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04106050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03996408
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT02953106
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT03221842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipients of C1-INH plus albumin
Trial: NCT04608344
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as single dose tablet orally.
Trial: NCT04608344
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as single dose tablet orally.
Trial: NCT03191864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Trial: NCT03144843
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
Trial: NCT00846703
Drug: 6-mercaptopurine, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine p.o. qd~Methotrexate p.o. qw
Trial: NCT00846703
Drug: 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)
Trial: NCT02152553
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02152553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01765829
Drug: Discontinuation antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction until withdrawal
Trial: NCT01765829
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
Trial: NCT02044874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01563367
Drug: Natriumklorid 9 mg/ml, Fresenius Kabi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
Trial: NCT00084214
Drug: STA-4783
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01790659
Drug: Paromomycin
RxNorm normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin alone
Trial: NCT00778102
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 2-hour iv infusion, day 1 every 2 weeks
Trial: NCT00778102
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 2-hour iv infusion, day 1 every 2 weeks
Trial: NCT00779532
Drug: NOMAC-E2 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
Trial: NCT01319279
Drug: Hydrocodone bitartrate extended-release tablet
RxNorm normalized name: hydrocodone bitartrate Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg (single dose)
Trial: NCT00787917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
Trial: NCT04516382
Drug: PTG-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug
Trial: NCT02487498
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Trial: NCT02487498
Drug: Placebo (QVA149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Trial: NCT04112160
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM injection of either normal saline or Ketorolac
Trial: NCT04112160
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT03241810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03785613
Drug: Reference Product R: Transtec patch (20 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
Trial: NCT03785613
Drug: Matching placebo patch to T1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch to T1.
Trial: NCT03785613
Drug: Matching placebo patch to T2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch to T2.
Trial: NCT03785613
Drug: Matching placebo patch to R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch to R.
Trial: NCT01802437
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
Trial: NCT03813186
Drug: ASTX727 + Day 2 Food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
Trial: NCT01088243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Trial: NCT03141983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
Trial: NCT00239564
Drug: IPX054 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX054 containing 25 mg carbidopa and 100 mg levodopa
Trial: NCT00239564
Drug: IPX054 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
Trial: NCT00239564
Drug: IPX054 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
Trial: NCT03590600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo: powder and solvent for oral suspension
Trial: NCT02526875
Drug: Telminuvo®Tab. 40/2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Trial: NCT01575275
Drug: aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03839875
Drug: Gynomax® XL Vaginal Ovule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tioconazole, tinidazole, lidocaine
Trial: NCT03738800
Drug: CD5789 Cream 200 µg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
Trial: NCT03738800
Drug: CD5789 Cream Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
Trial: NCT02072330
Drug: TAK-536CCB + Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
Trial: NCT00777361
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iv single dose, 4-hour infusion of 25 mg
Trial: NCT01674309
Drug: FOLFORINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTRAVENOUS administration
Trial: NCT01271998
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, oral, once daily for 3 days.
Trial: NCT02072330
Drug: TAK-536CCB + Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
Trial: NCT00777361
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution single dose of 50 mg
Trial: NCT00690079
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
Trial: NCT00690079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral admin. of doses at 11 days through a 12 days period.
Trial: NCT00147615
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02481011
Drug: antithrombotic drugs
RxNorm normalized name: Heparin group antithrombotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01472757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered via a new dry powder inhaler
Trial: NCT02956057
Drug: Polyethylene glycol / Ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00565916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
Trial: NCT03685396
Drug: hemostatic agents with oxidized and regenerated cellulosa
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
Trial: NCT04508179
Drug: 7HP349 Single Ascending Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
Trial: NCT04508179
Drug: Placebo Single Ascending Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Placebo Capsules, Single Ascending Dose (SAD)
Trial: NCT04508179
Drug: Placebo Multiple Ascending Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
Trial: NCT04508179
Drug: 7HP349 Food Effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part C: 7HP349 Capsules, Food Effect
Trial: NCT04489381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets administered orally twice daily with food for 5 days